- Report
- January 2026
- 220 Pages
Global
From €2238EUR$2,500USD£1,955GBP
- Report
- January 2026
- 180 Pages
Global
From €2238EUR$2,500USD£1,955GBP
- Report
- November 2025
- 200 Pages
Global
From €7116EUR$7,950USD£6,216GBP
- Clinical Trials
- July 2025
- 80 Pages
Global
From €1790EUR$2,000USD£1,564GBP
- Clinical Trials
- July 2025
- 280 Pages
Global
From €2685EUR$3,000USD£2,346GBP
- Drug Pipelines
- July 2025
- 280 Pages
Global
From €2685EUR$3,000USD£2,346GBP
- Drug Pipelines
- June 2025
- 150 Pages
Global
From €3357EUR$3,750USD£2,932GBP
- Report
- June 2025
- 150 Pages
Global
From €3357EUR$3,750USD£2,932GBP
- Report
- March 2026
- 371 Pages
Global
From €5237EUR$5,850USD£4,574GBP
- Report
- January 2026
- 181 Pages
Global
From €4028EUR$4,500USD£3,519GBP
- Report
- January 2026
- 180 Pages
Global
From €4028EUR$4,500USD£3,519GBP
- Report
- January 2026
- 182 Pages
Global
From €4028EUR$4,500USD£3,519GBP
- Report
- January 2026
- 180 Pages
Global
From €4028EUR$4,500USD£3,519GBP
- Report
- January 2026
- 180 Pages
Global
From €4028EUR$4,500USD£3,519GBP
- Report
- May 2025
- 185 Pages
Global
From €4028EUR$4,500USD£3,519GBP
- Report
- June 2025
- 400 Pages
Global
From €4430EUR$4,949USD£3,870GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2497EUR$2,789USD£2,181GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2497EUR$2,789USD£2,181GBP
- Report
- September 2025
- 149 Pages
Global
From €3580EUR$3,999USD£3,127GBP
- Report
- January 2026
- 297 Pages
Global
From €2238EUR$2,500USD£1,955GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more